201 filings
8-K
YMAB
Y-Mabs Therapeutics Inc
14 Mar 24
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
9:17am
8-K
YMAB
Y-Mabs Therapeutics Inc
4 Mar 24
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors
6:05am
S-8
YMAB
Y-Mabs Therapeutics Inc
29 Feb 24
Registration of securities for employees
5:04pm
10-K
2023 FY
YMAB
Y-Mabs Therapeutics Inc
Annual report
29 Feb 24
4:15pm
8-K
YMAB
Y-Mabs Therapeutics Inc
29 Feb 24
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
4:04pm
8-K
p2uck
9 Jan 24
Results of Operations and Financial Condition
6:45am
8-K
ymjehmj
13 Nov 23
Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
4:47pm
8-K
6ssncx ldx
18 Oct 23
Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director
4:09pm
8-K
0vl5bm vz
18 Oct 23
Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA
9:00am
8-K
nq4e82x
10 Aug 23
Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
4:30pm
8-K
llmx7470jx r3dbpc
9 Jun 23
Submission of Matters to a Vote of Security Holders
5:30pm
8-K
h797tryje6
26 May 23
Y-mAbs Announces Presentation of Naxitamab Data at ASCO
5:05pm
8-K
4imuvbq67krx61z3 ihf
23 May 23
Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil
9:41am
8-K
de8lu3x3ggpm9 tbj
8 May 23
Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial Guidance
4:10pm
EFFECT
1a4di
8 May 23
Notice of effectiveness
12:15am
CORRESP
sa77z02pt66sxqu66ee
2 May 23
Correspondence with SEC
12:00am
ARS
ecw5mj
28 Apr 23
Annual report to shareholders
6:11am